Reckitt Benckiser Group (OTCMKTS:RBGLY) Stock Rating Upgraded by Barclays

Reckitt Benckiser Group (OTCMKTS:RBGLY) was upgraded by equities researchers at Barclays from a “hold” rating to a “strong-buy” rating in a report released on Monday,Zacks.com reports.

RBGLY has been the topic of several other research reports. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Reckitt Benckiser Group in a research note on Monday, October 27th. Royal Bank Of Canada reiterated an “outperform” rating on shares of Reckitt Benckiser Group in a research note on Thursday, October 23rd. Three research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy”.

Reckitt Benckiser Group Stock Down 0.3%

Shares of RBGLY opened at $15.90 on Monday. Reckitt Benckiser Group has a one year low of $11.73 and a one year high of $15.98. The stock’s fifty day moving average is $15.46 and its 200-day moving average is $14.78. The company has a debt-to-equity ratio of 1.01, a current ratio of 0.56 and a quick ratio of 0.37.

About Reckitt Benckiser Group

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.